These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32785135)

  • 41. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
    Abena PM; Decloedt EH; Bottieau E; Suleman F; Adejumo P; Sam-Agudu NA; Muyembe TamFum JJ; Seydi M; Eholie SP; Mills EJ; Kallay O; Zumla A; Nachega JB
    Am J Trop Med Hyg; 2020 Jun; 102(6):1184-1188. PubMed ID: 32323646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.
    Haghjoo M; Golipra R; Kheirkhah J; Golabchi A; Shahabi J; Oni-Heris S; Sami R; Tajmirriahi M; Saravi M; Khatami M; Varnasseri M; Kiarsi M; Hejazi SF; Yousefzadeh Rahaghi M; Taherkhani M; Ashraf H; Keshmiri MS; Akbarzadeh MA; Bozorgi A; Mottaghizadeh F; Hedayat B; Heidarali M; Hajhossein Talasaz A
    Int J Clin Pract; 2021 Jul; 75(7):e14182. PubMed ID: 33759318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
    Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
    Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis.
    Risch HA
    Am J Epidemiol; 2020 Nov; 189(11):1218-1226. PubMed ID: 32458969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
    Gagnon LR; Sadasivan C; Yogasundaram H; Oudit GY
    Curr Heart Fail Rep; 2022 Dec; 19(6):458-466. PubMed ID: 36167917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection.
    Bajpai J; Pradhan A; Verma AK; Kant S
    World J Exp Med; 2022 May; 12(3):44-52. PubMed ID: 35765514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    Shah S; Das S; Jain A; Misra DP; Negi VS
    Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
    Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
    Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.
    Cattaneo D; Pasina L; Maggioni AP; Giacomelli A; Oreni L; Covizzi A; Bradanini L; Schiuma M; Antinori S; Ridolfo A; Gervasoni C
    Drugs Aging; 2020 Dec; 37(12):925-933. PubMed ID: 33150470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.
    Agstam S; Yadav A; Kumar-M P; Gupta A
    Indian Pacing Electrophysiol J; 2021; 21(1):36-43. PubMed ID: 33075484
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
    Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
    J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.
    Lammers AJJ; Brohet RM; Theunissen REP; Koster C; Rood R; Verhagen DWM; Brinkman K; Hassing RJ; Dofferhoff A; El Moussaoui R; Hermanides G; Ellerbroek J; Bokhizzou N; Visser H; van den Berge M; Bax H; Postma DF; Groeneveld PHP
    Int J Infect Dis; 2020 Dec; 101():283-289. PubMed ID: 33007454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis.
    Ren L; Xu W; Overton JL; Yu S; Chiamvimonvat N; Thai PN
    Front Pharmacol; 2020; 11():562777. PubMed ID: 33154723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
    Kumar J; Jain S; Meena J; Yadav A
    J Infect Chemother; 2021 Jun; 27(6):882-889. PubMed ID: 33678548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial.
    Tirupakuzhi Vijayaraghavan BK; Jha V; Rajbhandari D; Myatra SN; John O; Ghosh A; Bassi A; Arfin S; Kunigari M; Joshi R; Donaldson L; Hammond N; Venkatesh B;
    Trials; 2020 Aug; 21(1):754. PubMed ID: 32867852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
    Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
    Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.